However, similar to the approach in rGBM, VB-111 may require an additional targeted therapy to exert its optimal efficacy in this disease setting, such as Avastin, recently approved based on the AURELIA study.
Keeps $13 target, but read through the lines. PIG.
Many longs don't understand how wack it's balance sheet really is. You add to that the warrants that are converted this month & will be ready for sale if not sold already, PLUS $40 mil ATM PLUS $100 million shelf. This is the time to SELL this company.